Chemical formula: C₂₉H₅₃NO₅ Molecular mass: 495.735 g/mol PubChem compound: 3034010
Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
ATC code | Group title | Classification |
---|---|---|
A08AB01 | Orlistat | A Alimentary tract and metabolism → A08 Antiobesity preparations, excl. diet products → A08A Antiobesity preparations, excl. diet products → A08AB Peripherally acting antiobesity products |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Title | Information Source | Document Type | |
---|---|---|---|
XENICAL Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
XENICAL Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Orlistat is an active ingredient of these brands:
United States (US)Australia (AU)Brazil (BR)Canada (CA)Cyprus (CY)France (FR)Israel (IL)Italy (IT)New Zealand (NZ)Romania (RO)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.